Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment
Fulltext:
98048.pdf
Embargo:
until further notice
Size:
130.3Kb
Format:
PDF
Description:
Publisher’s version
Publication year
2011Source
Journal of Pediatric Hematology/Oncology, 33, 4, (2011), pp. e171-3ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Dermatology
Paediatrics - OUD tm 2017
Surgery
Radiology
Journal title
Journal of Pediatric Hematology/Oncology
Volume
vol. 33
Issue
iss. 4
Page start
p. e171
Page end
p. 3
Subject
IGMD 1: Functional imaging; N4i 1: Pathogenesis and modulation of inflammation; ONCOL 4: Quality of Care; Medical Imaging - Radboud University Medical Center; NCEBP 14: Cardiovascular diseases ONCOL 5: Aetiology, screening and detectionAbstract
Kaposiform hemangioendothelioma is a rare vascular tumor in children. Especially, in association with the Kasabach-Merritt Phenomenon it can be life threatening. The management of these patients is very difficult and an aggressive treatment regime is required. Several multimodality and chemotherapeutic regimens have been described but with variable success and many side effects. We present a 6-week-old boy with Kaposiform hemangioendothelioma and Kasabach-Merritt Phenomenon. Ongoing propranolol treatment with only 4 initial courses of vincristine resulted in a remission that lasted at least 1 year.
This item appears in the following Collection(s)
- Academic publications [248274]
- Electronic publications [135674]
- Faculty of Medical Sciences [94130]
Upload full text
Use your RU or RadboudUMC credentials to log in with SURFconext to upload a file for processing by the repository team.